A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
about
Epigenetic treatment of solid tumours: a review of clinical trialsEpigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatmentsClass I HDAC imaging using [ (3)H]CI-994 autoradiographyDetermination of chidamide in rat plasma by LC-MS and its application to pharmacokinetics study.Interpreting clinical assays for histone deacetylase inhibitors.Combination phenylbutyrate/gemcitabine therapy effectively inhibits in vitro and in vivo growth of NSCLC by intrinsic apoptotic pathwaysNonhistone protein acetylation as cancer therapy targets.Histone deacetylase inhibitors: insights into mechanisms of lethality.Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?Histone deacetylase inhibitors in lymphoma and solid malignancies.Targeting histone deacetylases for the treatment of diseaseNew clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer.Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis.The promise and failures of epigenetic therapies for cancer treatmentClass I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.Genetic and Chemical Screenings Identify HDAC3 as a Key Regulator in Hepatic Differentiation of Human Pluripotent Stem CellsHistone deacetylase inhibitors in cancer therapy
P2860
Q26773803-6D82C1B7-8AD9-4C70-A174-C76AD30FE0C2Q26828724-8DE186D9-D0B4-4A52-88DF-BB796C0B8041Q34353711-F310782D-2B5D-4EE7-ADAE-9DB5FD650B30Q34822075-42851627-51A2-4552-B86F-85BB3C58DE49Q35003657-7E3472E2-8796-4743-BB6D-B605E5D7CDA1Q35173372-DDECCBC9-35DF-4220-80DC-E25E43DD4492Q35739676-13000578-BF72-4F0B-8453-2F6CAE8764CAQ36219726-ABEE5F9B-F77B-44BE-9DB4-2CA2D3D665F9Q36654454-0237CF2F-BB77-44BA-9300-0FD3DA9D9272Q37118947-25A4F2B9-D7F4-44C4-B61A-6F9734ADFC9CQ37296159-550F1F6B-C5EA-41A5-BE3F-D58FD98B20B2Q37503780-3662356C-A726-4375-91AF-B19854308D37Q37970955-BAA73196-E6AB-4B59-9D48-97220F7680B1Q38119782-30C5A56C-83EB-47BA-AD63-ADF3F029EEADQ41150386-88558B9D-5BC0-4217-9E17-785D551F0649Q57176673-138E4221-3032-4D75-9F05-437F18E32381Q57272462-1A2F67D1-7674-46E3-B775-3EE254D7EE13
P2860
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
description
2004 nî lūn-bûn
@nan
2004 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A phase I study of the oral co ...... e inhibitor, and capecitabine.
@ast
A phase I study of the oral co ...... e inhibitor, and capecitabine.
@en
type
label
A phase I study of the oral co ...... e inhibitor, and capecitabine.
@ast
A phase I study of the oral co ...... e inhibitor, and capecitabine.
@en
prefLabel
A phase I study of the oral co ...... e inhibitor, and capecitabine.
@ast
A phase I study of the oral co ...... e inhibitor, and capecitabine.
@en
P2093
P356
P1433
P1476
A phase I study of the oral co ...... e inhibitor, and capecitabine.
@en
P2093
H L Kindler
K A Kimmel
M J Ratain
N J Vogelzang
R L Schilsky
S D Undevia
P304
P356
10.1093/ANNONC/MDH438
P577
2004-11-01T00:00:00Z